Last reviewed · How we verify

NCT04780555

Evaluation of Musculoskeletal System Symptoms and Biochemical Parameters in COVID-19

Completed Last updated 3 August 2021
What this trial tests

trial in Covid19 in 150 participants. Completed in 1 August 2021.

Timeline
1 March 2021
Primary endpoint
25 July 2021
1 August 2021

Quick facts

Lead sponsorAbant Izzet Baysal University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment150
Start date1 March 2021
Primary completion25 July 2021
Estimated completion1 August 2021
Sites1 location across Turkey (Türkiye)

Conditions studied

Sponsor

Abant Izzet Baysal University

Who can join

Adults 18 to 70, any sex, with Covid19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The neutrophil-lymphocyte ratio (NLR) used to demonstrate inflammatory status in recent years can be calculated by dividing the absolute neutrophil count by the absolute lymphocyte count at routine blood tests.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Covid19

Currently open trials in the same condition.

Other Abant Izzet Baysal University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04780555.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing